CoChat

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

Open access
Reardon, D A, Dresemann, G, Taillibert, S, Campone, M, van den Bent, M, Clement, P, Blomquist, E, Gordower, L, Schultz, H, Raizer, J, Hau, P, Easaw, J, Gil, M, Tonn, J, Gijtenbeek, A, Schlegel, U, Bergstrom, P, Green, S, Weir, A, Nikolova, Z · 2009 · British Journal of Cancer
Cited by 133

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs). METHODS: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS). RESULTS: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%). CONCLUSIONS: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjc.6605411

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 133

Metadata

Authors
Reardon, D. A., Dresemann, G., Taillibert, S., Campone, M., van den Bent, M., Clement, P., Blomquist, E., Gordower, L., Schultz, H., Raizer, J., Hau, P., Easaw, J., Gil, M., Tonn, J., Gijtenbeek, A., Schlegel, U., Bergstrom, P., Green, S., Weir, A., & Nikolova, Z.
Venue
British Journal of Cancer
Published
2009-11-10
Volume
101
Issue
12
Pages
1995-2004
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2127445947
Cited by
133
References
2
FWCI
6.80
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. https://app.cochat.ai/papers/10.1038/sj.bjc.6605411
The paper
Reardon, D. A., Dresemann, G., Taillibert, S., Campone, M., van den Bent, M., Clement, P., Blomquist, E., Gordower, L., Schultz, H., Raizer, J., Hau, P., Easaw, J., Gil, M., Tonn, J., Gijtenbeek, A., Schlegel, U., Bergstrom, P., Green, S., Weir, A., & Nikolova, Z. (2009). Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. British Journal of Cancer. https://doi.org/10.1038/sj.bjc.6605411

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.